completely
bioequivalent. The use of linezolid for the treatment of
bone and joint infections, including patients with infected
prostheses, has been described in several case series.8—10
Linezolid has been shown to have high activity against Staphylococcus
aureus and S. epidermidis, enterococci, and
streptococci.7,10 Some Gram-negative anaerobes and mycobacteria
are generally susceptible as well, whereas Enterobacteriaceae
and other Gram-negative bacteria are
resistant.7,10 From a tolerability point of view, linezolid
shows a favorable safety profile. The most common side
effects include anemia and thrombocytopenia, especially
when linezolid treatment is prolonged, as in bone and joint
infections.11